Northern Trust’s Aprea Therapeutics APRE Stock Holding History

Northern Trust’s Portfolio APRE Stock Details APRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$11K	Buy	+13,705	New	+$11.4K	﹤0.01%	4409
2023 Q1	–	Sell	-1,436	Closed	-$9.5K	–	4580
2022 Q4	$9.5K	Hold	1,436	–	–	﹤0.01%	4580
2022 Q3	$19K	Hold	1,436	–	–	﹤0.01%	4553
2022 Q2	$22K	Sell	1,436 -24	-2%	-$553	﹤0.01%	4607
2022 Q1	$54K	Sell	1,460 -288	-16%	-$11.8K	﹤0.01%	4515
2021 Q4	$100K	Sell	1,748 -22	-1%	-$1.94K	﹤0.01%	4424
2021 Q3	$181K	Buy	1,770 +143	+9%	+$13K	﹤0.01%	4219
2021 Q2	$159K	Sell	1,627 -3,659	-69%	-$338K	﹤0.01%	4231
2021 Q1	$539K	Sell	5,286 -385	-7%	-$44.9K	﹤0.01%	3793
2020 Q4	$559K	Sell	5,671 -230	-4%	-$109K	﹤0.01%	3698
2020 Q3	$2.84M	Buy	5,901 +358	+6%	+$200K	﹤0.01%	2876
2020 Q2	$4.3M	Buy	5,543 +1,484	+37%	+$974K	﹤0.01%	2611
2020 Q1	$2.82M	Buy	4,059 +89	+2%	+$65.3K	﹤0.01%	2652
2019 Q4	$3.64M	Buy	+3,970	New	+$2.19M	﹤0.01%	2778

Other funds holding APRE

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Diadema Partners Morristown, New Jersey $791M AUM 245.83% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Northern Trust's APRE Position: Q2 2026 in Review

Northern Trust opened a new position in Aprea Therapeutics (APRE) in Q2 2026: 13,705 shares worth $11K. The stake represents ﹤0.01% of the portfolio and ranks #4409 among its holdings. This is a return to the name: Northern Trust previously reported a position in APRE as recently as Q4 2022.

Northern Trust first reported a position in APRE in Q4 2019 and has held it in 14 quarters since. The position peaked at $4.3M in Q2 2020. 28 funds tracked by Wall St. Rank hold APRE as of Q2 2026.

Northern Trust held 13,705 shares of Aprea Therapeutics worth $11K as of Q2 2026.
Aprea Therapeutics was a new Northern Trust position in Q2 2026.
Aprea Therapeutics made up ﹤0.01% of Northern Trust's portfolio in Q2 2026, its #4409 holding.
Northern Trust first reported a position in Aprea Therapeutics in Q4 2019 and has held it in 14 quarters since.
Northern Trust's Aprea Therapeutics position peaked at $4.3M in Q2 2020.
28 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q2 2026.

Based on Northern Trust's 13F filing for Q2 2026, filed 13 Aug 2026.